Add Yahoo as a preferred source to see more of our stories on Google. The global healthcare community is bracing for one of its most formidable challenges: by 2050, global cancer cases are projected ...

With an eye toward better matching its targeted therapeutics to the patients who will benefit most, Incyte has turned to Agilent Technologies to develop companion diagnostics for its drugs. The duo ...

Pharmaceutical companies are keen to have a stake in the personalized medicine market, viewed as a growing trend in the future of healthcare and a significant source of life science innovation. As ...

Never has there been more information to enable a patient’s fight against cancer, but how does one select the right treatment? This is how companion diagnostics fit with precision medicine. Advances ...

Personalized medicine is continuing to evolve to the point where we have drug makers developing drugs that come with a companion diagnostic, developed with the help of a diagnostic partner. Arno ...

Dr. Madhuri Hegde explores the changing landscape of CDx, the technologies accelerating its progress, and the challenges ...

The FDA has bestowed a green light to a companion diagnostic for Pfizer’s recently approved hemophilia B gene therapy—because, at a cost of $3.5 million per dose, you want to make sure it will work.

- The DRP®-Dovitinib companion diagnostic demonstrated an ability to identify advanced renal cell carcinoma patients that have improved clinical benefit from dovitinib treatment, as compared to ...

Companion diagnostics in fields like oncology are well-known, but it’s their potential impact on psychiatry that is gaining attention and has the potential to shape the future of the industry.

TruSight Oncology Comprehensive is the first US FDA-approved, distributable comprehensive genomic profiling IVD kit with pan-cancer companion diagnostic claims The 500+ gene biomarker test advances ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced an agreement with Incyte that will bring together Agilent’s expertise and proven track record in the ...

Companion diagnostics in fields like oncology are well-known, but it’s their potential impact on psychiatry that is gaining attention and has the potential to shape the future of the industry.